These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 16010439)

  • 1. Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
    Coudray AM; Louvet C; Kornprobst M; Raymond E; André T; Tournigand C; Faivre S; De Gramont A; Larsen AK; Gespach C
    Int J Oncol; 2005 Aug; 27(2):553-61. PubMed ID: 16010439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
    Longley DB; Ferguson PR; Boyer J; Latif T; Lynch M; Maxwell P; Harkin DP; Johnston PG
    Clin Cancer Res; 2001 Nov; 7(11):3533-9. PubMed ID: 11705873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
    Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
    Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
    Backus HH; Pinedo HM; Wouters D; Kuiper CM; Jansen G; van Groeningen CJ; Peters GJ
    Oncol Res; 2000; 12(5):231-9. PubMed ID: 11417748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of pemetrexed in the treatment of colorectal cancer.
    Hochster H
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):54-6. PubMed ID: 12571812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
    Mullany S; Svingen PA; Kaufmann SH; Erlichman C
    Cancer Chemother Pharmacol; 1998; 42(5):391-9. PubMed ID: 9771954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase inhibition induces p53 dependent and independent cell death.
    Backus HH; Wouters D; van der Wilt CL; Kuiper CM; van Groeningen CJ; Pinedo HM; Peters GJ
    Adv Exp Med Biol; 2000; 486():303-6. PubMed ID: 11783505
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
    Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
    Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
    Azzariti A; Xu JM; Porcelli L; Paradiso A
    Biochem Pharmacol; 2004 Jul; 68(1):135-44. PubMed ID: 15183125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
    Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y
    Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
    Xu JM; Azzariti A; Tommasi S; Lacalamita R; Colucci G; Johnston PG; Church SW; Paradiso A
    Clin Colorectal Cancer; 2002 Nov; 2(3):182-8. PubMed ID: 12482336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
    Guichard S; Hennebelle I; Bugat R; Canal P
    Biochem Pharmacol; 1998 Mar; 55(5):667-76. PubMed ID: 9515577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase: a critical target for cancer chemotherapy.
    Rose MG; Farrell MP; Schmitz JC
    Clin Colorectal Cancer; 2002 Feb; 1(4):220-9. PubMed ID: 12450420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
    Markova B; Hähnel PS; Kasper S; Herbertz S; Schuler M; Breitenbuecher F
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):545-54. PubMed ID: 22203472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.